Scarica l'app Stockscreener
22.70
0.39%
-0.09
Dopo l'orario di chiusura:
22.70
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
2026-04-05 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Stockholders to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
PCRX Technical Analysis & Stock Price Forecast - Intellectia AI
Pacira (PCRX) BioSciences well-positioned with genicular outcomes registry evidence - msn.com
PCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
2026-04-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Investors to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. (PCRX) Stock Forecasts - Yahoo Finance
Analysts Set Expectations for PCRX Q1 Earnings - MarketBeat
(PCRX) Risk Channels and Responsive Allocation - Stock Traders Daily
2026-03-31 | Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira (PCRX) BioSciences Well-Positioned With Genicular Outcomes Registry Evidence - Insider Monkey
Hennion & Walsh Asset Management Inc. Acquires 87,210 Shares of Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Bitget
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting - Ortho Spine News
Study data linked EXPAREL to lower knee and spine surgery costs - Stock Titan
2026-03-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Connect | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A. - marketbeat.com
Bull Run: Is Pacira BioSciences Inc impacted by rising ratesQuarterly Profit Report & Expert Curated Trade Ideas - baoquankhu1.vn
Vanguard amends Schedule 13G/A after internal realignment (PCRX) - stocktitan.net
Absci, DigitalOcean And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRX) and Encourages Stockholders to Learn More About the Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira BioSciences (NASDAQ:PCRX) Price Target Cut to $25.00 by Analysts at Barclays - MarketBeat
PCRX: Barclays Lowers Price Target to $25, Maintains Equal-Weigh - GuruFocus
2026-03-24 | Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation | NDAQ:PCRX | Press Release - Stockhouse
Pacira faces board fight as activist investor criticizes CEO pay, missed earnings - MSN
(PCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 By Investing.com - Investing.com India
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - GuruFocus
Pacira BioSciences’ chief medical officer sells $74k in stock By Investing.com - Investing.com Australia
Insider Selling: Pacira BioSciences (NASDAQ:PCRX) Insider Sells 3,261 Shares of Stock - MarketBeat
Froimson Mark sells Pacira BioSciences (PCRX) shares for $10905 - Investing.com UK
Pacira BioSciences (PCRX) director receives 6,163 restricted stock units in equity grant - Stock Titan
Pacira BioSciences (NASDAQ: PCRX) CMO sells 3,261 company shares - Stock Titan
Pacira BioSciences (PCRX) director sells 500 common shares in open market - Stock Titan
Pacira BioSciences unveils support hub for caregivers addressing chronic pain - Traders Union
[144] Pacira BioSciences, Inc. SE... | PCRX SEC FilingForm 144 - Stock Titan
Pacira BioSciences (NASDAQ:PCRX) Shares Down 4.7%Time to Sell? - MarketBeat
PCRX (NASDAQ: PCRX) insider sale notice lists 3 share lots - Stock Titan
Profit Review: Will Pacira BioSciences Inc benefit from seasonality2026 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn
Radcliffe Capital Management L.P. Takes $1.23 Million Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences advances non opioid pain therapies to transform patient care - Traders Union
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation - Sahm
Activist DOMA takes 7.3% Pacira (NASDAQ: PCRX) stake and targets CEO, board - Stock Titan
Pacira BioSciences responds to DOMA director nominations - Investing.com Australia
DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. - Morningstar
[DFAN14A] Pacira BioSciences, Inc. SEC Filing - Stock Titan
Activist hedge fund pushes Pacira BioSciences to sell itself - The Business Journals
Pacira Faces Board Fight As Activist Investor Criticizes CEO Pay, Missed Earnings - Benzinga
Pacira BioSciences responds to DOMA director nominations By Investing.com - Investing.com Canada
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):